Acquisition of SSI Strategy by Clinigen

BDO's multidisciplinary Life Sciences & Healthcare deals team has provided deep sector expertise and strategic advice to Clinigen, regarding its investment in SSI Strategy, a strategic move that strengthens Clinigen's sector and geographical positioning.

SSI Strategy and Clinigen together are set to become a comprehensive global partner for the biopharma industry, supporting clients from early-stage strategy through to commercialisation.

- Our LS&H Transaction Services team delivered comprehensive financial due diligence and SPA support, helping Clinigen navigate the complexities of the deal with confidence
- Our LS&H Transaction Tax team delivered multinational tax due diligence and advice limiting risk and maximising upside in the deal
- Our LS&H Strategy and Commercial Due Diligence team provided buy-side CDD support, offering critical insights into SSI Strategy’s market positioning and growth potential
- Our Value Creation Services team conducted a red flag integration review and synergy assessment, ensuring Clinigen could unlock maximum value post-acquisition.
 

“It was a pleasure to work with the whole BDO LS&H Deals team on our investment in SSI. Finding partners who grasp the importance of our Global Pathfinder mission is essential, and their experience within the health and life sciences sector meant they were able to provide truly value-add services and continued support as the deal progressed. They were responsive, collaborative and insightful, helping us take another step forward in accelerating access to critical medicines.”

Keith Byrne, Group Head of Corporate Development, Clinigen

The BDO project team included:

Graeme Hurst, Lewis Winston, Olivia Wakefield, Zak Holdaway (Financial due diligence)
Carol Hindle, Will Searle, Masinnie Tran, Peter McCall (Tax) 
Gurpal Ahluwalia, Dodi Behiri, Sarah Postlethwaite, Andrew Goodluck, Charles Jervis (CDD)
Richard Austin, Ross McWhir, Alex Meldrum (VCS)
Laurence Mills and John Rouse (SPA)